相关实验视频

Updated: Jan 9, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

使用人工智能辅助亚型精密治疗提高了HR+/HER2-乳腺癌的治疗疗效:LINUX试验

Lei Fan¹, Wen-Juan Zhang¹, Hui-Ping Li²

¹Department of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

|December 5, 2025

概括

基于人工智能驱动的亚型 (SNF) 的精密疗法显示,对抗CDK4/6抑制剂的转移性乳腺癌患者的反应率有所改善. 基于亚型的治疗方法在大多数亚型中比医生选择更有效.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
人工智能在医学中的应用

背景情况:

激素受体阳性/人表皮生长因子受体2-阴性 (HR+/HER2-) 转移性乳腺癌往往会对循环素依赖性激酶4/6抑制剂 (CDK4/6i) 产生耐药性.
确定这种患者群体的有效精确治疗方法仍然是一个临床挑战.

研究的目的:

评估基于亚型的精密治疗与医生选择的治疗在HR+/HER2-转移性乳腺癌患者获得CDK4/6i耐药性的疗效.
使用人工智能 (AI) 识别不同的患者亚型,以进行有针对性的治疗选择.

主要方法:

该LINUX试验 (NCT05594095) 是一个多中心的,随机的,受控的II期平台试验.
105名患者使用AI被分为四种相似性网络融合 (SNF) 亚型.
患者被随机分配,接受基于亚型的精密疗法 (N=70) 或医生选择的治疗 (N=35).

主要成果:

客观响应率 (ORR) 在基于亚型的组中优于SNF亚型的对照组:SNF1 (10%vs0%),SNF2 (65%vs30%),SNF3 (40%vs30%) 和SNF4 (70%vs20%).
基于亚型的精密疗法显示出显著的益处,特别是在SNF2和SNF4亚型.
3-4级与治疗相关的不良事件在各组之间是相似的 (37%).

结论:

人工智能驱动的亚型可以指导HR+/HER2-转移性乳腺癌CDK4/6i后抗性的有效精确疗法选择.
基于亚型的精密疗法提供了一种优越的治疗策略,与医生对特定患者亚组的选择相比.
需要在第三阶段试验中进一步验证,以证实这些发现.

关键词:

人工智能辅助的人工智能在HR+/HER2−中.乳腺癌乳腺癌乳腺癌精密处理精密处理基于亚型的治疗方法

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...